A practical guide about biosimilar data for health care providers treating inflammatory diseases
Joseph Markenson,1,2 Daniel F Alvarez,3 Ira Jacobs,4 Carol Kirchhoff5 1Department of Rheumatology, 2Department of Medicine, Hospital for Special Surgery, New York, NY, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Chesterfield, MO, USA Abstract: To make informed dec...
Enregistré dans:
Auteurs principaux: | Markenson J, Alvarez DF, Jacobs I, Kirchhoff C |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f9f26565da4f46dba6052ea2c7079196 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Biosimilars and the extrapolation of indications for inflammatory conditions
par: Tesser JRP, et autres
Publié: (2017) -
Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
par: Yazici Y, et autres
Publié: (2018) -
Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
par: Al Sulais E, et autres
Publié: (2020) -
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
par: Mysler E, et autres
Publié: (2021) -
A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population
par: Yazici Y, et autres
Publié: (2018)